← Human Trials & Peer-Reviewed Studies
Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38
Plain-language guide to PMID 24501094 (2014): double-blind randomized controlled trial study of VIP (Vasoactive Intestinal Peptide) and PACAP in 24 patients, migraine.
Key Facts
- PMID
- 24501094
- Journal
- Brain : a journal of neurology
- Year
- 2014
- Study type
- Randomized Controlled Trial
- Authors
- Amin FM et al. (12 authors)
- DOI
- 10.1093/brain/awt369
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of VIP (Vasoactive Intestinal Peptide) and PACAP in the context of migraine, published as a randomized controlled trial.
Pituitary adenylate cyclase-activating polypeptide-38 (PACAP38) and vasoactive intestinal polypeptide are structurally and functionally closely related but show differences in migraine-inducing properties.
Mechanisms responsible for the difference in migraine induction are unknown.
Who Took Part
The abstract describes 24 patients taking part.
PubMed indexes the participants as young adults and adults, women only.
How the Study Was Run
The researchers set it up as a randomized, double-blind and crossover study.
The patients were allocated by chance, so the VIP (Vasoactive Intestinal Peptide) group and the comparison group should start out alike.
As a double-blind VIP (Vasoactive Intestinal Peptide) study, the assignments were hidden from both participants and investigators until the end.
Each person switched between VIP (Vasoactive Intestinal Peptide) and the comparison at some point, usually with a gap in between.
What Was Measured
Pituitary adenylate cyclase-activating polypeptide-38 (PACAP38) and vasoactive intestinal polypeptide are structurally and functionally closely related but show differences in migraine-inducing properties.
Here, for the first time, the researchers present a head-to-head comparison study of the immediate and long-lasting observations of the migraine-inducing, arterial, physiological and biochemical responses comparing PACAP38 and vasoactive intestinal polypeptide.
The subject headings attached to it are Cerebral Arteries, Magnetic Resonance Angiography, Migraine Disorders, Pituitary Adenylate Cyclase-Activating Polypeptide, Tryptases and Vasoactive Intestinal Peptide.
Author keywords: human pain models, imaging and migraine pathogenesis.
What This Means in Plain Language
The paper is a randomized, double-blind and crossover study of VIP (Vasoactive Intestinal Peptide) and PACAP in 24 patients in people with migraine.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 2014 (Brain : a journal of neurology), a journal based in England.
More context: the VIP (Vasoactive Intestinal Peptide) compound page and the PACAP compound page, Migraine research.
Our Notes on the Compounds
VIP (Vasoactive Intestinal Peptide): A 28-amino-acid neuropeptide that relaxes smooth muscle and calms immune activity; aviptadil is a synthetic form.
PACAP: Pituitary adenylate cyclase-activating polypeptide, a 38-amino-acid neuropeptide studied in migraine provocation research.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.